Search results for "From ACP Journal Club"


 
Results 61 - 70 of about 116 for "From ACP Journal Club".
Sort by: Relevance | Newest | Oldest

Review: In type 2 diabetes, sodium–glucose cotransporter 2 inhibitors do not increase major CV events or mortality

The meta-analysis included 37 trials that compared canagliflozin, dapagliflozin, or empagliflozin to placebo or other active antidiabetic treatments.
https://diabetes.acponline.org/archives/2017/02/10/6.htm
10 Feb 2017

Guideline: The USPSTF recommends low- to moderate-dose statins to prevent CVD in selected adults 40 to 75 years of age

The U.S. Preventive Services Task Force (USPSTF) issued a recommendation on use of statins for primary prevention of cardiovascular disease (CVD).
https://diabetes.acponline.org/archives/2017/04/14/6.htm
14 Apr 2017

In type 1 diabetes, adding liraglutide to insulin increased hypoglycemia and hyperglycemia with ketosis

The study authors concluded that the negative effects observed would limit clinical use of liraglutide in patients with type 1 diabetes.
https://diabetes.acponline.org/archives/2017/01/13/6.htm
13 Jan 2017

Semaglutide reduced a composite of CV events at two years in patients with type 2 diabetes and high CV risk

Semaglutide, a new once-weekly glucagon-like peptide-1 (GLP-1) analogue, reduced cardiovascular (CV) events compared to placebo, according to a manufacturer-sponsored study.
https://diabetes.acponline.org/archives/2017/02/10/7.htm
10 Feb 2017

Intensive glucose-lowering in type 2 diabetes was linked to hypoglycemia in high-complexity patients

More than 20% of patients with type 2 diabetes received treatment more intensive than that recommended by HbA1c-based guidelines, a study of Medicare patients found.
https://diabetes.acponline.org/archives/2016/10/07/5.htm
7 Oct 2016

In patients with type 2 diabetes and CVD, empagliflozin reduced incident or worsening nephropathy at 3.1 y

A subanalysis of a trial of empagliflozin for patients with cardiovascular disease (CVD) found lower rates of nephropathy in those randomized to empagliflozin rather than placebo.
https://diabetes.acponline.org/archives/2016/11/11/7.htm
11 Nov 2016

Review: In adults with diabetes, aspirin does not prevent CV events compared with placebo

A review published prior to the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes trial found that aspirin only reduced cardiovascular events in diabetes patients with pre-existing cardiovascular disease.
https://diabetes.acponline.org/archives/2016/12/09/5.htm
9 Dec 2016

In patients with type 2 diabetes and high CV risk, liraglutide reduced a composite CV outcome at a median 3.8 y

The study's primary composite outcome was first occurrence of death from cardiovascular (CV) causes, nonfatal (including silent) myocardial infarction, or nonfatal stroke.
https://diabetes.acponline.org/archives/2016/11/11/6.htm
11 Nov 2016

In type 2 diabetes treated with high-dose insulin, liraglutide reduced HbA1c

The hypoglycemia rate was higher in the first month after initiation of liraglutide, but the overall hypoglycemia rate over the 6-month follow-up was similar in liraglutide and placebo patients.
https://diabetes.acponline.org/archives/2016/11/11/5.htm
11 Nov 2016

Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulfonylureas increases hypoglycemia

Adding dipeptidyl peptidase-4 (DPP-4) inhibitors to sulfonylureas was associated with 1 excess case of hypoglycemia for every 17 patients in the first 6 months of treatment, the systematic review and meta-analysis found.
https://diabetes.acponline.org/archives/2016/09/16/5.htm
16 Sep 2016

Result Page: Prev   2   3   4   5   6   7   8   9   10   11   Next